It can be concluded that, (i) the novel 11beta-HSD1 inhibitor BI 187004 is safe and well tolerated after single dose in healthy male volunteers with overweight or obesity; (ii) there is significant and over 24 h sustained 11beta-HSD1 enzyme inhibition in liver and AT; (iii) the promising pharmacodynamic effects justify further investigation of BI 187004 in multiple dose trials. This evidence concerns the gene HSD11B1 and obesity disorder.